Navigation Links
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Date:6/9/2008

CINCINNATI Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in the June 9 issue of Cancer Cell.

"We document early biological processes where human leukemia stem cells can be altered to form a particular type, or lineage, of leukemia by the factors they are exposed to in the microenvironment of blood-forming tissues," said James Mulloy, Ph.D., a researcher in the division of Experimental Hematology/Cancer Biology at Cincinnati Children's and the study's corresponding author. "These new details about molecular events associated with MLL, and the new mouse model we developed for the study, will allow testing of novel therapeutic strategies for MLL patients. They will also yield information that may be directly translatable into clinical interventions."

Leukemia is the most common blood cancer and includes several diseases, according to the National Cancer Institute. The four major types are acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML).

Mixed lineage leukemia (MLL) results when chromosome mutations involving the MLL gene fuse with certain partner genes. These so-called translocations result in the MLL gene being rearranged to send instructions to create either AML or ALL. This process can start before birth, and while MLL translocations are associated with 7 percent of AML cases and 10 percent of ALL cases, they are found in a majority of infants with acute leukemia. In some instances the clinical disease is diagnosed within a few months of birth.

Dr. Mulloy and his colleagues discovered that disrupting a protein known to regulate cell growth (Rac1) has potential for curbing MLL. The discovery came about a
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Human breast tumors microenvironment primes them for metastasis
2. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
3. Coalition to Protect Floridas Drivers Applauds Governor Crist for Adding PIP to Special Session
4. Hospitals and the Coalition to Protect Floridas Drivers Applaud Lawmakers for Reviving No-Fault Insurance
5. Male Drivers are Hitting, Killing Most Child Pedestrians, New Study Shows
6. AUDIO from Medialink and The Hartford: When Alzheimers Puts Drivers at the Crossroads
7. DNA (driver of nicotine addiction)
8. Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma
9. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
10. Teen Driving Experts at The Childrens Hospital of Philadelphia Support New Recommendations From the New Jersey Teen Driver Study Commission
11. Many Teen Drivers Dont Think Theyre Inexperienced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from the Icahn School ... complete genomes by combining high-throughput DNA sequencing with genome mapping. The methodology enabled ... with human disease, but previously difficult to detect. The study was published today ...
(Date:6/29/2015)... Fernando Valley, CA (PRWEB) , ... June 29, 2015 , ... ... non-invasive treatments designed to lift and tighten sagging skin. Ulthera is a special treatment ... surgery. Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly ...
(Date:6/29/2015)... ... June 29, 2015 , ... The ... Chemical Technology of The Hong Kong Polytechnic University (PolyU) has developed a new ... of edible oils has been a long-term issue in food safety, and becomes ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... company serving the Twin Cities area, provides money-saving tactics during a season of ... Twin Cities’ residents, addressing water conservation and other economical practices. , According to ...
(Date:6/29/2015)... ... , ... BaliniSports has been announced as an official sponsor and apparel provider ... This year’s contestants will be wearing pieces from the BaliniSports collection during practice sessions ... on to represent the state in the Miss Teen USA competition. , “BaliniSports ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3Health News:BaliniSports Announced as Sponsor of the Miss Teen Nevada 2016 Competition 2
... ion beams developed at GSI is characterized by an excellent ... been routinely in use for a little over one year. ... the tumor type, but also on the genetic disposition and ... first time, scientists at GSI Helmholtzzentrum fr Schwerionenforschung have irradiated ...
... FRIDAY, Dec. 17 (HealthDay News) -- Children and adults with ... higher risk of death than those with other types of ... known as lupus, affects one or more parts of the ... Up to 80 percent of children with lupus suffer kidney ...
... Graph app, researchers in the ADVANCE project at NJIT ... help women scientists and engineers supercharge their careers. ... sheets. They,re webs of human interaction," said Nancy Steffen-Fluhr, ... and the ADVANCE project leader. "The complex structure of ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) -- U.S. ... type of brain cancer in children. Gene sequencing reveals ... abnormalities than comparable adult tumors. The discovery that MB ... tumors could further attempts to understand what triggers the cancer ...
... hard time keeping a lid on their feelings, especially ... reality shows, psychologists have found. But they,re better than ... a stressful situation and empathizing with the less fortunate, ... A team of researchers led by UC ...
... Italy determined that radiofrequency ablation (RFA) is a safe ... cirrhotic patients. The high repeatability of RFA is advantageous ... Results of this 10-year retrospective study are available in ... journal published by Wiley-Blackwell on behalf of the American ...
Cached Medicine News:Health News:Samples of vital human tumor tissue irradiated with ions for the first time 2Health News:Kidney Disease Could Be More Deadly for Kids With Lupus 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 3Health News:Gene Research Brings Insight Into Deadly Childhood Brain Tumor 2Health News:Emotional intelligence peaks as we enter our 60s, research suggests 2Health News:Emotional intelligence peaks as we enter our 60s, research suggests 3Health News:Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation 2
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: